Molecular markers associated with response to chemotherapy in gastro-entero-pancreatic neuroendocrine tumors.
暂无分享,去创建一个
E. Raymond | P. Bedossa | P. Ruszniewski | A. Couvelard | V. Rebours | P. Lévy | O. Hentic | P. Hammel | D. O'Toole | M. Zappa | D. O’Toole
[1] N. Funel,et al. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] E. Steyerberg,et al. Microsatellite instability, mismatch repair deficiency, and BRAF mutation in treatment-resistant germ cell tumors. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[3] H. Lenz,et al. Thymidylate synthase gene variations: predictive and prognostic markers , 2009, Molecular Cancer Therapeutics.
[4] F. Boccardo,et al. Clinical and pathological response to primary chemotherapy in patients with locally advanced breast cancer grouped according to hormonal receptors, Her2 status, grading and Ki-67 proliferation index. , 2009, Anticancer research.
[5] M. Somerfield,et al. American Society of Clinical Oncology provisional clinical opinion: testing for KRAS gene mutations in patients with metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Hung,et al. Induction of Akt activity by chemotherapy confers acquired resistance. , 2009, Journal of the Formosan Medical Association = Taiwan yi zhi.
[7] S. Fox,et al. The key hypoxia regulated gene CAIX is upregulated in basal-like breast tumours and is associated with resistance to chemotherapy , 2009, British Journal of Cancer.
[8] Jeffrey W. Clark,et al. O-Methylguanine DNA Methyltransferase Deficiency and Response toTemozolomide-BasedTherapy in Patients with Neuroendocrine Tumors , 2008 .
[9] Mitch Dowsett,et al. Emerging Biomarkers and New Understanding of Traditional Markers in Personalized Therapy for Breast Cancer , 2008, Clinical Cancer Research.
[10] P. Bedossa,et al. Overexpression of the Oxygen Sensors PHD-1, PHD-2, PHD-3, and FIH Is Associated with Tumor Aggressiveness in Pancreatic Endocrine Tumors , 2008, Clinical Cancer Research.
[11] S. Willich,et al. Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors , 2008, Cancer.
[12] K. Miyazaki,et al. Expression of the hMLH1 gene is a possible predictor for the clinical response to 5-fluorouracil after a surgical resection in colorectal cancer. , 2008, Oncology reports.
[13] G. Scagliotti,et al. Thymidylate Synthase Expression in Gastroenteropancreatic and Pulmonary Neuroendocrine Tumors , 2008, Clinical Cancer Research.
[14] F. Meric-Bernstam,et al. Antitumor activity of rapamycin and octreotide as single agents or in combination in neuroendocrine tumors. , 2007, Endocrine-related cancer.
[15] A. Scarpa,et al. Consensus Guidelines for the Management of Patients with Liver Metastases from Digestive (Neuro)endocrine Tumors: Foregut, Midgut, Hindgut, and Unknown Primary , 2007, Neuroendocrinology.
[16] A. Scarpa,et al. TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system , 2007, Virchows Archiv.
[17] Carmen Blanco-Aparicio,et al. PTEN, more than the AKT pathway. , 2007, Carcinogenesis.
[18] P. Bedossa,et al. Identification of potential therapeutic targets by gene-expression profiling in pancreatic endocrine tumors. , 2006, Gastroenterology.
[19] A. Scarpa,et al. TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system , 2006, Virchows Archiv : an international journal of pathology.
[20] R. Callaghan,et al. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer. , 2006, Current opinion in pharmacology.
[21] D. O'Toole. Tumeurs endocrines de l’estomac, de l’intestin grêle, du côlon et du rectum , 2006 .
[22] A. Harris,et al. Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression , 2004, British Journal of Cancer.
[23] P. Ruszniewski,et al. Chemotherapy for Gastro-Enteropancreatic Endocrine Tumours , 2004, Neuroendocrinology.
[24] M. Sekiguchi,et al. Loss of expression of DNA repair enzymes MGMT, hMLH1, and hMSH2 during tumor progression in gastric cancer , 2003, Gastric Cancer.
[25] P. Dhawan,et al. Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression. , 2002, Cancer Research.
[26] C. Axiotis,et al. Differential Expression of the PTEN Tumor Suppressor Protein in Fetal and Adult Neuroendocrine Tissues and Tumors: Progressive Loss of PTEN Expression in Poorly Differentiated Neuroendocrine Neoplasms , 2002, Applied immunohistochemistry & molecular morphology : AIMM.
[27] M. Fukushima,et al. Prognostic significance of thymidylate synthase activity in bladder carcinoma , 2001, Cancer.
[28] D. Harpole,et al. The prognostic value of molecular marker analysis in patients treated with trimodality therapy for esophageal cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[29] P Komminoth,et al. Mutation and expression analyses reveal differential subcellular compartmentalization of PTEN in endocrine pancreatic tumors compared to normal islet cells. , 2000, The American journal of pathology.
[30] M. Fukushima,et al. Intratumoral expression of thymidylate synthase and dihydropyrimidine dehydrogenase in non-small cell lung cancer patients treated with 5-FU-based chemotherapy. , 2000, International journal of oncology.
[31] R. Gelber,et al. Prognostic importance of thymidylate synthase expression in early breast cancer. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] C. Doglioni,et al. Improved histologic and clinicopathologic criteria for prognostic evaluation of pancreatic endocrine tumors. , 2009, Human pathology.
[33] K. Syrjänen,et al. Oncoprotein Bcl-2 and microsatellite instability are associated with disease-free survival and treatment response in colorectal cancer. , 2008, Oncology reports.
[34] M. Dewhirst,et al. RNA aptamer-targeted inhibition of NF-kappa B suppresses non-small cell lung cancer resistance to doxorubicin. , 2008, Molecular therapy : the journal of the American Society of Gene Therapy.
[35] D. O’Toole. [Current trend: endocrine tumors of the stomach, small bowel, colon and rectum]. , 2006, Gastroenterologie clinique et biologique.